Gastroenterology
Browse by
Research outputs from the Gastroenterology department at the RD&E.
Recent Submissions
-
Hospital admissions from alcohol-related acute pancreatitis during the COVID-19 pandemic: A single-centre study
(IS Publishing, 2022-09-06)BACKGROUND: The United Kingdom government introduced lockdown restrictions for the first time on 23 March 2020 due to coronavirus disease 2019 (COVID-19) pandemic. These were partially lifted on 15 June and further eased ... -
Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK
(Nature, 2022-11-07)Ferric derisomaltose (FDI; Monofer) is used in clinical practice to treat iron deficiency, but the safety and efficacy of FDI has not been robustly evaluated in a large real-world study. This retrospective, multicentre, ... -
Surgical Methods of Fistula Closure in fistulating perianal Crohn's Disease
(Wiley, 2022-11-25) -
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
(BMJ, 2022-07-01)The COVID-19 pandemic has raised considerable concerns that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have an increased risk of SARS-CoV-2 acquisition, ... -
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
(BMJ, 2022-07-28)OBJECTIVE: Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 ... -
Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
(Wiley, 2022-09-01)BACKGROUND: During illness, adaptations of the hypothalamic-pituitary-thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine-to-thyroxine ... -
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
(Elsevier, 2022-06-15)BACKGROUND: The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities and might vary by factors such as ethnicity. ... -
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
(Elsevier, 2022-09-08)BACKGROUND: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive ... -
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report
(Wellcome, 2022-06-01)Background: At the outset of the COVID-19 pandemic, there was no routine comprehensive hospital medicines data from the UK available to researchers. These records can be important for many analyses including the effect of ... -
The first international Delphi consensus statement on Laparoscopic Gastrointestinal surgery
(Elsevier, 2022-08-01)BACKGROUND: Laparoscopic surgery has almost replaced open surgery in many areas of Gastro-Intestinal (GI) surgery. There is currently no published expert consensus statement on the principles of laparoscopic GI surgery. ... -
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients
(Oxford University Press, 2022-05-10)BACKGROUND AND AIMS: Age is a major prognostic factor for COVID-19 outcomes. The effect of inflammatory bowel disease [IBD] activity on COVID-19 is unclear. We examined the relationship between IBD activity and COVID-19 ... -
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
(Wiley, 2022-08-29)BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would ... -
Multisystem inflammatory syndrome in children
(Canadian Medical Association, 2022-07-11) -
Outcomes of patients with non-lower gastrointestinal cancer diagnosed via the lower gastrointestinal two-week-wait service
(Royal College of Surgeons, 2022-05-26)INTRODUCTION: Patients referred via lower gastrointestinal two-week-wait (LGI-2WW) services deemed at 'low risk' of LGI cancer may have delayed or no investigation. However, 20% of patients diagnosed with cancer via the ... -
Clinician preferences in the treatment of acutely symptomatic hernia: the 'MASH' survey
(Royal College of Surgeons, 2022-02-23)INTRODUCTION: There is limited high-quality evidence to guide the management of acute hernia presentation. The aim of this study was to survey surgeons to assess current trends in assessment, treatment strategy and operative ... -
Elective splenectomy in patients with non-Hodgkin lymphoma: Does the size of the spleen affect surgical outcomes?
(Korean Association of Hepato-Biliary-Pancreatic Surgery, 2022-02-16)BACKGROUNDS/AIMS: Splenectomy in patients with non-Hodgkin lymphoma (NHL) is performed to relieve abdominal symptoms, treat hypersplenism or confirm diagnosis. Excision of a very large spleen is technically challenging and ... -
Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
(BMJ Publishing Group, 2022-01-01)INTRODUCTION: Acute severe ulcerative colitis (ASUC) traditionally requires inpatient hospital management for intravenous therapies and/or colectomy. Ambulatory ASUC care has not yet been evaluated in large cohorts. AIMS: ... -
Editor's Choice - February 2022
(Wiley, 2022-02-01)